ILD Risk Elevated in RA, PsA After Starting DMARDs
The risk for interstitial lung disease in patients with PsA during the first 5 years was five times higher than for the general population, and the risk was not modified by methotrexate use.
Sella Aarrestad Provan Aarrestad Provan Iain Mcinnes European Congress Boehringer Ingelheim University Of Glasgow
Source: medscape.com